Published in J Exp Med on June 21, 1999
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med (2003) 1.26
Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun (2000) 1.13
Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog (2007) 1.09
Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei. Infect Immun (2006) 0.99
Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th1-response. Clin Exp Immunol (2003) 0.93
Histopathological outcome of Leishmania major-infected BALB/c mice is improved by oral treatment with N-acetyl-l-cysteine. Immunology (2003) 0.91
Influence of parasite load on the ability of type 1 T cells to control Leishmania major infection. Infect Immun (2002) 0.76
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Interleukin-13: central mediator of allergic asthma. Science (1998) 14.05
Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 10.76
The regulation of immunity to Leishmania major. Annu Rev Immunol (1995) 8.05
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71
Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med (1997) 5.56
IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity (1998) 4.65
IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol (1992) 4.43
Induction of TH1 and TH2 immunity in neonatal mice. Science (1996) 4.25
The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med (1995) 4.21
Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med (1995) 3.65
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med (1985) 2.92
Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med (1994) 2.70
Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med (1995) 2.52
Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol (1986) 2.38
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35
Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol (1994) 2.31
CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 2.31
Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med (1994) 2.22
Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity (1994) 2.19
A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol (1991) 2.15
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 1.94
Resistance to Leishmania major induced by tolerance to a single antigen. Science (1996) 1.87
In vivo production and function of IL-12 p40 homodimers. J Immunol (1997) 1.72
Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci U S A (1995) 1.59
T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci U S A (1998) 1.58
Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania-infected cells. Eur J Immunol (1998) 1.55
Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1. Infect Immun (1995) 1.54
Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol (1995) 1.53
IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today (1996) 1.52
Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A (1994) 1.47
Genetic regulation of commitment to interleukin 4 production by a CD4(+) T cell-intrinsic mechanism. J Exp Med (1998) 1.44
Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J Immunol (1994) 1.43
Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells. Eur J Immunol (1994) 1.40
Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J Immunol (1997) 1.39
Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol (1991) 1.35
The Th1/Th2 balance in autoimmunity. Curr Opin Immunol (1995) 1.32
In differentiated CD4+ T cells, interleukin 4 production is cytokine-autonomous, whereas interferon gamma production is cytokine-dependent. Proc Natl Acad Sci U S A (1997) 1.31
Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev (1992) 1.27
Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol (1994) 1.27
Limited role of CD28-mediated signals in T helper subset differentiation. J Exp Med (1996) 1.21
IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol (1993) 1.21
A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J Exp Med (1997) 1.14
Blockade of CD86 ameliorates Leishmania major infection by down-regulating the Th2 response. J Infect Dis (1996) 1.14
Targeted activation of CD8 cells and infection of beta 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J Immunol (1993) 1.13
Impaired Th2 subset development in the absence of CD4. Immunity (1997) 1.12
Differences in the degree of depletion, rate of recovery, and the preferential elimination of naive CD4+ T cells by anti-CD4 monoclonal antibody (GK1.5) in young and aged mice. J Immunol (1995) 1.11
Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell Immunol (1998) 1.10
A role for CD4 in peripheral T cell differentiation. J Exp Med (1997) 1.08
Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect Immun (1998) 1.08
Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol (1992) 1.04
Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun (1998) 1.00
Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol (1988) 0.99
Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest (1997) 0.98
Administration of IL-12 during ongoing immune responses fails to permanently suppress and can even enhance the synthesis of antigen-specific IgE. Int Immunol (1995) 0.91
Therapeutic monoclonal antibodies. Br J Rheumatol (1995) 0.77
Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med (1993) 5.75
In vivo production and function of IL-12 p40 homodimers. J Immunol (1997) 1.72
Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun (1994) 1.71
Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol (1995) 1.53
IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol (1993) 1.21
Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell Immunol (1998) 1.10
IFN-gamma-independent production of IL-12 during murine endotoxemia. J Immunol (1996) 1.02
Immunoregulation of murine leishmaniasis by interleukin-12. Res Immunol (1996) 0.81
Cytotoxic and mutagenic effects of the photodynamic action of chloroaluminum phthalocyanine and visible light in L5178Y cells. Photochem Photobiol (1989) 0.77
Increased capacity for interleukin-2 synthesis parallels disease progression in mice infected with Leishmania major. Infect Immun (1998) 0.76